타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Ziv-Aflibercept) National Cancer Institute (NCI)·FRα 1 trials | ||||
|---|---|---|---|---|---|
Overview Program | Ziv-Aflibercept | Sonidegib | Rigosertib | polymerase chain reaction | Antiretroviral Therapy |
Overview Company | National Cancer Institute (NCI) | Mayo Clinic | Vanderbilt-Ingram Cancer Center | OSI Pharmaceuticals | National Cancer Institute (NCI) |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | FRα | FRα | FRα | FRα | FRα |
Overview Indication | Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Colorectal Carcinoma | Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recurrent Melanoma; Stage IV Melanoma | AIDS-Related Non-Hodgkin Lymphoma; Clinical Stage III Cutaneous Melanoma AJCC v8 |
Overview Phase | PHASE_1 | PHASE_1 | PHASE_2 | PHASE_2 | PHASE_1 |
Overview Status | RECRUITING | RECRUITING | RECRUITING | ACTIVE | ACTIVE |
Overview Content status | Limited Data | Limited Data | Limited Data | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Watch | Development Signal · Watch | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Watch |
Overview Approval status | Investigational | Investigational | Investigational | Investigational | Investigational |
MoA Mechanism | — | — | — | targets were mainly associated with ion transport, membrane potential regulation, muscle system processes, immune signaling, apoptosis, endocrine resistance, and AGE-RAGE signaling pathway | — |
MoA Biomarker | — | — | — | Biomarkers for Breast Cancer: A Case-Control Study | — |
Clinical Program phase | PHASE_1 | PHASE_1 | PHASE_2 | PHASE_2 | PHASE_1 |
Clinical Trial activity | — | — | — | No active/completed counts | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Ziv-Aflibercept) National Cancer Institute (NCI)·FRα 1 trials | ||||
|---|---|---|---|---|---|
Overview Program | Ziv-Aflibercept | Sonidegib | Rigosertib | polymerase chain reaction | Antiretroviral Therapy |
Overview Company | National Cancer Institute (NCI) | Mayo Clinic | Vanderbilt-Ingram Cancer Center | OSI Pharmaceuticals | National Cancer Institute (NCI) |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | FRα | FRα | FRα | FRα | FRα |
Overview Indication | Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Colorectal Carcinoma | Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recurrent Melanoma; Stage IV Melanoma | AIDS-Related Non-Hodgkin Lymphoma; Clinical Stage III Cutaneous Melanoma AJCC v8 |
Overview Phase | PHASE_1 | PHASE_1 | PHASE_2 | PHASE_2 | PHASE_1 |
Overview Status | RECRUITING | RECRUITING | RECRUITING | ACTIVE | ACTIVE |
Overview Content status | Limited Data | Limited Data | Limited Data | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Watch | Development Signal · Watch | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Watch |
Overview Approval status | Investigational | Investigational | Investigational | Investigational | Investigational |
MoA Mechanism | — | — | — | targets were mainly associated with ion transport, membrane potential regulation, muscle system processes, immune signaling, apoptosis, endocrine resistance, and AGE-RAGE signaling pathway | — |
MoA Biomarker | — | — | — | Biomarkers for Breast Cancer: A Case-Control Study | — |
Clinical Program phase | PHASE_1 | PHASE_1 | PHASE_2 | PHASE_2 | PHASE_1 |
Clinical Trial activity | — | — | — | No active/completed counts | — |
추천 비교
추천 비교